Entrada Therapeutics, Inc. (TRDA) intrinsic value & 10-year financials
Entrada Therapeutics, Inc. (TRDA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue shrank 55.6% a year to $25.4M, with an average return on invested capital of -5.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.37
- Market cap
- $180.8M
- Revenue (FY2025)
- $25.4M
- Revenue growth (7-yr CAGR)
- -55.6%
- ROIC (10-yr avg)
- -5.6%
- Free cash flow (FY2025)
- -$129.6M
TRDA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $25.4M | -$143.8M | -$3.47 | -$129.6M | -621.1% | -49.2% |
| FY2024 | $210.8M | $65.6M | $1.68 | -$44.7M | 22.3% | 15.1% |
| FY2023 | $129.0M | -$6.7M | -$0.20 | $134.2M | -2.5% | -0.8% |
| FY2022 | — | -$94.6M | -$3.02 | -$96.7M | — | -52.6% |
| FY2021 | — | -$51.2M | -$1.63 | -$55.4M | — | -39.8% |
| FY2020 | — | -$26.5M | -$4.80 | -$27.9M | — | 93.6% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Entrada Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Entrada Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.6% ROIC.
Entrada Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Entrada Therapeutics, Inc. is modeled at -55.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-148.88 per share.